UPDATE : Thursday, May 23, 2019
상단여백
Xtandi adds indication for non-metastatic castration-resistant prostate cancer by Kim Yun-mi 2019-02-21 15:10
84% of breast cancer patients are in working age in Korea by Kim Yun-mi 2019-02-20 14:52
[News Focus] Will MSD’s new antidiabetic SGLT-2 inhibitor prove effective? by Kim Yun-mi 2019-02-19 14:31
‘Hair loss drug Propesia works well for Koreans in long term’ by Kim Yun-mi 2019-02-18 16:38
Hanmi’s RaboneD dominates osteoporosis therapy market by Kim Yun-mi 2019-02-18 14:23
라인
MSD leads rapidly growing antidiabetic DPP-4 inhibitors market by Kim Yun-mi 2019-02-15 14:31
Direct-acting antivirals reduce death risk for hepatitis C patients: study by Kim Yun-mi 2019-02-14 14:59
Blood-thinning NOAC market expands 30% in 2018 by Kim Yun-mi 2019-02-14 12:12
Price cut, expanded indication to prop up cholesterol-reducing PCSK9 inhibitors by Kim Yun-mi 2019-02-13 16:11
AbbVie’s new hepatitis C treatment outpaces Gilead’s rival drugs by Kim Yun-mi 2019-02-12 15:56
라인
Gilead’s hepatitis B drug posts disappointing sales in 2018 by Kim Yun-mi 2019-02-11 15:29
Sales of antidiabetic SGLT-2 inhibitors expand 40% in 2018 by Kim Yun-mi 2019-02-11 14:35
Sanofi seeks to add cholesterol-lowering drug’s new indication in Korea by Kim Yun-mi 2019-02-08 16:12
Multinationals prepare next-generation pneumococcal vaccines by Kim Yun-mi 2019-02-08 12:02
MSD’s immunotherapy Keytruda outpaces BMS’ Opdivo in sales by Kim Yun-mi 2019-02-07 14:40
라인
Dementia drug Exelon’s insurance coverage expanded for Parkinson’s disease by Kim Yun-mi 2019-02-01 17:02
‘Alunbrig works better for ALK-positive non-small cell lung cancer’ by Kim Yun-mi 2019-02-01 15:38
Pfizer’s lung cancer drug Xalkori threatened by new rivals by Kim Yun-mi 2019-01-30 12:34
여백
여백
여백
Back to Top